Biomea Fusion, Inc. (BMEA:NASDAQ) closed at $1.26 on October 13, 2026, down 7.35% on the day. The stock trades 43.7% below its 52-week high of $2.24 and 44.5% above its 52-week low of $0.872. Over the past year, it lost 24.6%. Biomea Fusion, Inc. is part of the Health Care sector.
| 5D | 1M | 6M | 1Y |
|---|---|---|---|
| -11.27% | -29.21% | -42.99% | -24.55% |
In 252 trading sessions since October 13, 2025, BMEA closed higher on 122 days (48%). Its best day was April 7, 2026 (+25.83%) and its worst was September 23, 2026 (-15.29%). The stock moved 10% or more in a single session 12 times. It opened at least 5% above the previous day's high 3 times.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The companies lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
Find more stocks like BMEA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.